1269822-97-0

Upstream product

• 72652-34-7 1-(4-acetyl-1H-pyrrol-2-yl)-2,2,2-trichloroethan-1-one 
• 1269822-96-9 4-hydroxy-7H-pyrrolo[2,3-c]pyridazine-6-carboxylic acid 
• 1269822-95-8 methyl 4-hydroxy-7H-pyrrolo[2,3-c]pyridazine-6-carboxylate 
• 1269824-46-5 methyl 4-acetyl-5-amino-1H-pyrrole-2-carboxylate 
• 1269822-94-7 methyl 4-acetyl-5-nitro-1H-pyrrole-2-carboxylate 
• 1269822-93-6 1-(4-acetyl-5-nitro-1H-pyrrol-2-yl)-2,2,2-trichloroethanone 

Downstream Products

• 1269823-69-9 2-(7H-pyrrolo[2,3-c]pyridazin-4-yl)aniline 
• 1269823-02-0 4-chloro-7H-pyrrolo[2, 3-c]pyridazine 

Relevant academic research and scientific papers

NOVEL 3,4-DISUBSTITUTED-1H-PYRROLO[2,3-B]PYRIDINES AND 4,5-DISUBSTITUTED-7H-PYRROLO[2,3-C]PYRIDAZINES AS LRRK2 INHIBITORS

The present invention provides novel 3,4-disubstituted-1 H-pyrrolo[2,3- Jb]pyridine derivatives and 4,5-disubstituted-7H-pyrrolo[2,3-c]pyridazine derivatives of Formula (I), and the pharmaceutically acceptable salts thereof (I) wherein R1, R2, R3, R4 and X are as defined in the specification. The invention is also directed to pharmaceutical compositions comprising the compounds of formula (I) and to use of the compounds in the treatment of diseases associated with LRRK2, such as neurodegenerative diseases including Parkinson's disease or Alzheimer's disease, cancer, Crohn's disease or leprosy.

HETEROCYCLIC COMPOUNDS AS JANUS KINASE INHIBITORS

The invention provides compounds of formula (I) or a salt thereof as described herein. The invention also provides pharmaceutical compositions comprising a compound of formula (I), processes for preparing compounds of formula (I), intermediates useful for preparing compounds of formula I and therapeutic methods for suppressing an immune response or treating cancer or a hematologic malignancy using compounds of formula (I).